Compare Abeona Therapeutics Inc (ABEO) vs Trump Media and Technology Group Corp (DJT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Trump Media and Technology Group Corp — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Trump Media and Technology Group Corp trades at $8.18 (market cap $2.25B). The key difference: Trump Media and Technology Group Corp is far larger — about 6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | DJT | |
|---|---|---|
Market Cap | $373.32M | $2.25B |
Sector | Health | Media |
52-Week High | $7.23 | $19.86 |
52-Week Low | $4.17 | $7.06 |
Enterprise Value | $228.22M | $2.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
DJT trades at $8.66, up 1.41% today, with a bullish technical signal from moving averages despite neutral oscillators. Fundamentally, the company reported minimal revenue of $3.68M in 2025 with a massive net loss of -$712M, resulting in negative profit margins and ROE. Recent news highlights significant stock declines, with the company's market value dropping nearly 75% from its peak amid strategic shifts including a planned merger with TAE Technologies.
The outlook remains highly speculative with severe profitability challenges offset by potential catalysts from the TAE merger. Key risks include persistent losses, minimal revenue growth, and high volatility. Institutional sentiment is cautious given the extreme valuation metrics and operational uncertainties facing the social media platform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →
